News Release

Glucagon-like peptide 1 receptor agonist use and vertebral fracture risk in type 2 diabetes

JAMA Surgery

Peer-Reviewed Publication

JAMA Network

About The Study: In this cohort of patients with type 2 diabetes, glucagon-like peptide 1 receptor agonist (GLP-1 RA) use was associated with significantly lower risks of vertebral compression fractures and related surgical interventions compared with nonuse, suggesting bone protective benefits of GLP-1 RAs. 

Corresponding Author: To contact the corresponding author, Yu Chang, MD, email yuchang111235@gmail.com.

To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/

(doi:10.1001/jamasurg.2025.5372)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamasurgery/fullarticle/10.1001/jamasurg.2025.5372?guestAccessKey=ca195cca-5413-4736-a54f-62662c356e1d&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=121025


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.